Notably, axitinib in combination with delantercept, an ALK1 fusion protein which acts as a trap receptor against BMP 9 and 10, was unable to improve PFS in patients with refractory renal cell carcinoma compared to axitinib plus placebo. Here, ACVRL1 is linked to hereditary clear cell renal cell carcinoma.